Talis Biomedical Corp. (TLIS) delivers precise infectious disease testing as it is devoted to progressing health equity and outcomes. The company plans the production and marketing of novel testing facilities on its Talis One platform to allow low-cost and swift molecular testing.

TLIS stock price in the early trading session of March 16, 2022, at the time of writing, dropped by 30.7% to be $1.17.

TLIS: Key Financials

On March 15, 2022, TLIS released the consolidated financial statement for Q4 or three months ended on December 31, 2021. Some key points are discussed here.

Revenue

Grant revenues in Q4 2021 were $0.9 million corresponding to $0.2 million for the equivalent quarter of 2020. Its grant revenue gained $0.62 million YoY. The company missed the revenue target of $1.2 million

EPS

Net loss in Q4 2021 was $28.7 million corresponding to $44.2 million in the same quarter of 2020. The company’s net loss declined over the yearly span.

TLIS: Events and Happenings

On December 08, 2021, TLIS reported the appointment of Rob Kelley as its new Chief Executive Officer and Director with immediate effect. He served as the Chief Commercial Officer of the company and was promoted to the rank of CEO. Ex CEO Brian Blaser had stepped down from his position due to personal commitments.

On December 02, 2021, TLIS announced the grant of an inducement award to its CEO by the Board of Directors of the company. The grant was awarded pursuant to its Inducement Plan 2021. On November 08, 2021, TLIS updated on the grant of Emergency Use Authorization by FDA to its Talis One COVID-19 Test Platform. The system updates the molecular testing results in 30 minutes.

Conclusion

TLIS stock is continuously in plunging mode for the past year as an outcome of the pandemic constraints imposed globally. The company suffered a recent blow in Wednesday’s early trading as it announced the financial report. The revenue target was missed by the company.